Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial

被引：0

作者：

Grunwald, Viktor

Motzer, Robert J.

Keizman, Daniel

Bedke, Jens

Schmidinger, Manuela

Staehler, Michael D.

Matveev, Vsevolod B.

George, Saby

Hutson, Thomas E.

Vaishampayan, Ulka N.

Merchan, Jaime R.

Eto, Masatoshi

Rha, Sun Young

Waddell, Tom

Sabbatini, Roberto

Barthelemy, Philippe

Burgents, Joseph E.

Ren, Min

Brown, Ian

Choueiri, Toni K.

机构：

[1] Univ Hosp Essen, Essen, Germany

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[4] Klinikum Stuttgart, Dept Urol, Stuttgart, Germany

[5] Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany

[6] Med Univ Vienna, Vienna, Austria

[7] Univ Hosp Munich, Munich, Germany

[8] Minist Hlth Russian Federat, State Budgetary Inst NN Blokhin Natl Med Res Ctr, Moscow, Russia

[9] Roswell Park Canc Inst, Buffalo, NY 14263 USA

[10] Texas Oncol, Dallas, TX USA

[11] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[12] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[13] Kyushu Univ, Fukuoka, Japan

[14] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea

[15] Christie NHS Fdn Trust, Manchester, Lancs, England

[16] Univ Hosp Modena, Modena, Italy

[17] Strasbourg European Canc Inst, Strasbourg, France

[18] Merck & Co Inc, Rahway, NJ 07065 USA

[19] Eisai Inc, Nutley, NJ USA

[20] Eisai Ltd, Hatfield, Herts, England

[21] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4524

引用

页数：1

共 50 条

[21] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
Gruenwald, V
Powles, T.
Kopyltsov, E.
Kozlov, V
Alonso, Gordoa T.
Eto, M.
Hutson, T.
Motzer, R.
Winquist, E.
Maroto, P.
Keam, B.
Procopio, G.
Wong, S.
Melichar, B.
Rolland, F.
Oya, M.
Rodriguez-Lopez, K.
Saito, K.
Smith, A.
Porta, C.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 25 - 25
[22] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
Choueiri, Toni
Plimack, Elizabeth
Powles, Thomas
Voss, Martin
Gurney, Howard
Silverman, Rachel
Perini, Rodolfo
Rodriguez-Lopez, Karla
Rini, Brian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
[23] Pembrolizumab plus lenvatinib (P plus L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
Yan, Kevin
Rane, Pratik
Schmidinger, Manuela
Peer, Avivit
Druyts, Eric
Burgents, Joseph E.
Sundaram, Murali
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 422 - 422
[24] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
Choueiri, Toni K.
Plimack, Elizabeth R.
Powles, Thomas
Voss, Martin H.
Gurney, Howard
Silverman, Rachel Kloss
Perini, Rodolfo F.
Rodriguez-Lopez, Karla
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[25] New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma
Saillant, Arnaud
Borchiellini, Delphine
BULLETIN DU CANCER, 2022, 109 (7-8) : 737 - +
[26] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Hawkins, Robert
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio J.
Borchiellini, Delphine
Szczylik, Cezary
Markus, Maurice
McDermott, Raymond S.
Bedke, Jens
Tartas, Sophie
Chang, Yen-Hwa
Tamada, Satoshi
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Powles, Thomas
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
[27] Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
Gruenwald, Viktor
Mckay, Rana R.
Buchler, Tomas
Eto, Masatoshi
Park, Se Hoon
Takagi, Toshio
Zanetta, Sylvie
Keizman, Daniel
Suarez, Cristina
Negrier, Sylvie
Lee, Jae Lyun
Santini, Daniele
Bedke, Jens
Staehler, Michael
Kollmannsberger, Christian
Choueiri, Toni K.
Motzer, Robert J.
Burgents, Joseph E.
Xie, Ran
Okpara, Chinyere E.
Powles, Thomas
INTERNATIONAL JOURNAL OF CANCER, 2025, 156 (07) : 1326 - 1335
[28] Efficacy of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma: a systematic review
Budianto, C. J.
Sabran, M. Z.
Hutauruk, C. E. O. L.
Purushotama, N. B. S. A.
Kurniawan, A.
Huang, I.
ANNALS OF ONCOLOGY, 2024, 35 : S1400 - S1400
[29] Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
Motzer, Robert
George, Saby
Merchan, Jaime R.
Hutson, Thomas E.
Song, Xun
Perini, Rodolfo F.
Xie, Ran
Bapat, Urmi
Puente, Javier
ONCOLOGIST, 2023, 28 (06): : 501 - 509
[30] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Choueiri, Toni K.
Albiges, Laurence
Haanen, John B. A. G.
Larkin, James M. G.
Uemura, Motohide
Pal, Sumanta K.
Gravis, Gwenaelle
Campbell, Matthew T.
Penkov, Konstantin
Lee, Jae-Lyun
Ching, Keith A.
Mu, Xinmeng Jasmine
Wang, Xiao
Zhang, Weidong
Wang, Jing
Chudnovsky, Aleksander
di Pietro, Alessandra
Robbins, Paul B.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →